Boston Scientific (BSX) Tops Q4 EPS by 2c; Offers Q1 EPS Guidance Below Consensus, FY20 EPS Mid-Point Outlook Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. CHWY
4. SPCX
5. NAVN
6. USO
7. HUMA
8. CME
9. cASY
10. INTC

Go back to Boston Scientific (BSX) Tops Q4 EPS by 2c; Offers Q1 EPS Guidance Below Consensus, FY20 EPS Mid-Point Outlook Below Consensus

Boston Scientific Announces Results For Fourth Quarter And Full Year 2019

February 5, 2020 6:30 AM EST

MARLBOROUGH, Mass., Feb. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an operational1 basis and 7.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP earnings of $3.996 billion or $2.83 per share (EPS), compared to GAAP earnings of $386 million or $0.27 per share a year ago and achieved adjusted earnings per share of $0.46 for the period, compared to $0.39 a year ago. Reported GAAP earnings include a... More